Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Tarih
2008
Yazar
Havrdova, Eva
Limmroth, Volker
Polman, Chris H.
Kappos, Ludwig
Schmierer, Klaus
Yousry, Tarek A.
Yang, Minhua
ERAKSOY, Mefküre
Meluzinova, Eva
Rektor, Ivan
Dawson, Katherine T.
Sandrock, Alfred W.
O'Neill, Gilmore N.
Gold, Ralf
Miller, David H.
MacManus, David G.
Üst veri
Tüm öğe kaydını göster
Özet
Background Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis.
Bağlantı
http://hdl.handle.net/20.500.12627/179589
https://doi.org/10.1016/s0140-6736(08)61619-0
Koleksiyonlar